Retrospective review compares one-week and three-week adjuvant radiotherapy regimens in breast cancer patients, highlighting treatment differences and patient outcomes.
Background: A 1-week, ultra-hypofractionated adjuvant radiation regimen has been found to be non-inferior to the standard 3-week regimen in women with early breast cancer. Aim: The study aimed to compare the patient and treatment characteristics of women receiving a 1-week (26 Gy in 5 fractions) and standard 3-week (40 Gy in 15 fractions) adjuvant radiotherapy schedule. Setting: A radiation oncology unit in a quaternary state hospital, Charlotte Maxeke Johannesburg Academic Hospital, in South Africa. Methods: A retrospective review of medical records of women who received adjuvant breast radiotherapy between June 2020 and February 2022. Patient characteristics, treatment characteristics and acute toxicities were compared between those treated with the 1-week (26 Gy in 5 fractions) and the standard 3-week (40 Gy in 15 fractions) regimens. Results: Of 123 patients included, the median age was 51 years (range 29–75); 53.6% had stage III disease. Thirteen per cent received the 1-week regimen, and 87% received the
No takes yet. Share an insight, caveat, or question.
Choma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: